Company / SG&A Expense
Immuneering Corp SG&A Expense History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$15.6M
FY2023
5-year range
$3.1M / $15.6M
FY2021-FY2023
Trend
+88.7%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $3M to $16M over the past 2 years.
Based on SEC 10-K filings.
$16M in FY2023.
Increased from $3M to $16M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, sg&a expense increased 88.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $15.6M | +88.7% |
| FY2022 | $8.3M | +166.0% |
| FY2021 | $3.1M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026